Special Issue

Antimicrobial Peptides and Antimicrobial Nanomaterials in Biomedicine

Message from the Guest Editor

The development of antibiotics is one of the greatest medical achievements of the 20th Century, saving countless lives. However, as the use of these drugs increased, so did bacterial resistance. Antibiotic resistance is growing faster than it was expected to, being considered a main public health challenge and one of the biggest threats to global health and development.

Using antimicrobial peptides (AMPs) and antimicrobial nanomaterials is an excellent strategy to overcome this problem.

AMPs have a large spectrum of activity and low propensity to induce bacteria resistance. Nonetheless, their in vivo performance may be affected as they tend to self-aggregate and undergo enzymatic degradation, which often leads to toxicity issues as high concentrations are required to overcome these drawbacks. The answer to overcome this problem may dwell in their immobilization onto biomaterials.

Authors are kindly invited to submit original papers, communications, and reviews regarding the potential of Antimicrobial Peptides and Antimicrobial Nanomaterials to be published in this Special Issue of Pharmaceutics.

Guest Editor

Dr. Paula Parreira

i3S-Instituto de Investigação e Inovação em Saúde, Universidade do Porto. 4200-135 Porto. Portugal

Deadline for manuscript submissions

closed (20 September 2023)



Pharmaceutics

an Open Access Journal by MDPI

Impact Factor 5.5 CiteScore 10.0 Indexed in PubMed



mdpi.com/si/164850

Pharmaceutics
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
pharmaceutics@mdpi.com

mdpi.com/journal/pharmaceutics





an Open Access Journal by MDPI

Impact Factor 5.5 CiteScore 10.0 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

Pharmaceutics (ISSN 1999-4923) is an online open access journal on the science and technology of pharmaceutics and biopharmaceutics. The scientific community, the wider community and the general public have unlimited and free access to the content as soon as a paper is published; this open access to your research ensures your findings are shared with the widest possible audience. Please consider publishing your impressive work in this high quality journal. We would be pleased to welcome you as one of our authors.

Editor-in-Chief

Prof. Dr. Patrick J. Sinko

Ernest Mario School of Pharmacy, Rutgers, The State University of New Jersey, William Levine Hall, Room 225C, 160 Frelinghuysen Road, Piscataway, NJ 08854-8020, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 14.9 days after submission; acceptance to publication is undertaken in 3.3 days (median values for papers published in this journal in the first half of 2025).

